{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:50:19Z","timestamp":1783486219207,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T00:00:00Z","timestamp":1612310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T00:00:00Z","timestamp":1612310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PRIN 2017YTWKWH"],"award-info":[{"award-number":["PRIN 2017YTWKWH"]}],"id":[{"id":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s12020-021-02634-z","type":"journal-article","created":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T18:02:56Z","timestamp":1612375376000},"page":"358-366","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Long-term management of lenvatinib-treated thyroid cancer patients: a real-life experience at a single institution"],"prefix":"10.1007","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6162-5819","authenticated-orcid":false,"given":"Tommaso","family":"Porcelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Luongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Sessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Klain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Masone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Troncone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Bellevicine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schlumberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Salvatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,3]]},"reference":[{"key":"2634_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"B.R. Haugen, E.K. Alexander, K.C. Bible, G. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G. Randolph, A. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D. Steward, R.M. Tuttle, L. Wartofsky, 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1\u2013133 (2016)","journal-title":"Thyroid"},{"key":"2634_CR2","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJMoa2005651","volume":"383","author":"LJ Wirth","year":"2020","unstructured":"L.J. Wirth, E. Sherman, B. Robinson, B. Solomon, H. Kang, J. Lorch, F. Worden, M. Brose, J. Patel, S. Leboulleux, Y. Godbert, F. Barlesi, J.C. Morris, T.K. Owonikoko, D.S.W. Tan, O. Gautschi, J. Weiss, C. de la Fouchardi\u00e8re, M.E. Burkard, J. Laskin, M.H. Taylor, M. Kroiss, J. Medioni, J.W. Goldman, T.M. Bauer, B. Levy, V.W. Zhu, N. Lakhani, V. Moreno, K. Ebata, M. Nguyen, D. Heirich, E.Y. Zhu, X. Huang, L. Yang, J. Kherani, S.M. Rothenberg, A. Drilon, V. Subbiah, M.H. Shah, M.E. Cabanillas, Efficacy of selpercatinib in RET-altered thyroid cancers. N. Engl. J. Med. 383, 825\u2013835 (2020)","journal-title":"N. Engl. J. Med."},{"key":"2634_CR3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ecl.2018.10.009","volume":"48","author":"SP Weitzman","year":"2019","unstructured":"S.P. Weitzman, S.I. Sherman, Novel drug treatments of progressive radioiodine-refractory differentiated thyroid cancer. Endocrinol. Metab. Clin. North Am. 48, 253\u2013268 (2019)","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"2634_CR4","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","volume":"384","author":"MS Brose","year":"2014","unstructured":"M.S. Brose, C.M. Nutting, B. Jarzab, R. Elisei, S. Siena, L. Bastholt, C. de la Fouchardiere, F. Pacini, R. Paschke, Y.K. Shong, S.I. Sherman, J.W.A. Smit, J. Chung, C. Kappeler, C. Pe\u00f1a, I. Moln\u00e1r, M. Schlumberger, Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384, 319\u2013328 (2014)","journal-title":"Lancet"},{"key":"2634_CR5","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"M. Schlumberger, M. Tahara, L.J. Wirth, B. Robinson, M.S. Brose, R. Elisei, M.A. Habra, K. Newbold, M.H. Shah, A.O. Hoff, A.G. Gianoukakis, N. Kiyota, M.H. Taylor, S.B. Kim, M.K. Krzyzanowska, C.E. Dutcus, B. de las Heras, J. Zhu, S.I. Sherman, Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372, 621\u2013630 (2015)","journal-title":"N. Engl. J. Med"},{"key":"2634_CR6","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1200\/JCO.2016.71.6472","volume":"35","author":"MS Brose","year":"2017","unstructured":"M.S. Brose, F.P. Worden, K.L. Newbold, M. Guo, A. Hurria, Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT trial. J. Clin. Oncol. 35, 2692\u20132699 (2017)","journal-title":"J. Clin. Oncol."},{"key":"2634_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ejca.2019.05.031","volume":"118","author":"LD Locati","year":"2019","unstructured":"L.D. Locati, A. Piovesan, C. Durante, M. Bregni, M.G. Castagna, S. Zovato, M. Giusti, T. Ibrahim, E. Puxeddu, G. Fedele, G. Pellegriti, G. Rinaldi, D. Giuffrida, F. Verderame, F. Bertolini, C. Bergamini, A. Nervo, G. Grani, S. Rizzati, S. Morelli, I. Puliafito, R. Elisei, Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. Eur. J. Cancer 118, 35\u201340 (2019)","journal-title":"Eur. J. Cancer"},{"key":"2634_CR8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1089\/thy.2017.0205","volume":"28","author":"A Berdelou","year":"2018","unstructured":"A. Berdelou, I. Borget, Y. Godbert, T. Nguyen, M.E. Garcia, C.N. Chougnet, A. Ferru, C. Buffet, O. Chabre, O. Huillard, S. Leboulleux, M. Schlumberger, Lenvatinib for the treatment of radioiodine-refractory thyroid cancer in real-life practice. Thyroid 28, 72\u201378 (2018)","journal-title":"Thyroid"},{"key":"2634_CR9","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1089\/thy.2019.0022","volume":"29","author":"EK Lee","year":"2019","unstructured":"E.K. Lee, S.M. Kim, B.H. Kim, M.J. Kim, D.J. Lim, M.H. Kim, D.Y. Shin, H.C. Kang, B.C. Ahn, S.W. Kim, H.Y. Ahn, Y.J. Park, Lesion-based evaluation predicts treatment response to lenvatinib for radioactive iodine-refractory differentiated thyroid cancer: a Korean Multicenter Retrospective Study. Thyroid 29, 1811\u20131819 (2019)","journal-title":"Thyroid"},{"key":"2634_CR10","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1089\/thy.2019.0221","volume":"30","author":"C Masaki","year":"2020","unstructured":"C. Masaki, K. Sugino, N. Saito, J. Akaishi, K. Hames, C. Tomoda, A. Suzuki, K. Matsuzu, T. Uruno, K. Ohkuwa, W. Kitagawa, M. Nagahama, K. Ito, Efficacy and limitations of lenvatinib therapy for radioiodine-refractory differentiated thyroid cancer: real-world experiences. Thyroid 30, 214\u2013221 (2020)","journal-title":"Thyroid"},{"key":"2634_CR11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1530\/EJE-19-0763","volume":"182","author":"MD Aydemirli","year":"2020","unstructured":"M.D. Aydemirli, E. Kapiteijn, K.R.M. Ferrier, N. Ottevanger, T.P. Links, A.N.A. van der Horst-Schrivers, K.E. Broekman, R.H.H. Groenwold, J. Zwaveling, Effectiveness and toxicity of lenvatinib in refractory thyroid cancer: Dutch real-life data. Eur. J. Endocrinol. 182, 131\u2013138 (2020)","journal-title":"Eur. J. Endocrinol."},{"key":"2634_CR12","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1089\/thy.2019.0476","volume":"30","author":"E Song","year":"2020","unstructured":"E. Song, M. Kim, E.Y. Kim, B.H. Kim, D.Y. Shin, H.C. Kang, B.C. Ahn, W.B. Kim, Y.K. Shong, M.J. Jeon, D.J. Lim, Lenvatinib for radioactive iodine\u2010refractory differentiated thyroid carcinoma and candidate biomarkers associated with survival: a multicenter study in Korea. Thyroid 30, 732\u2013738 (2020)","journal-title":"Thyroid"},{"key":"2634_CR13","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s12020-020-02290-9","volume":"69","author":"F Jerkovich","year":"2020","unstructured":"F. Jerkovich, I. Califano, F. Bueno, J.M. Carrera, R. Giglio, E. Abelleira, F. Pitoia, Real-life use of lenvatinib in patients with differentiated thyroid cancer: experience from Argentina. Endocrine 69, 142\u2013148 (2020)","journal-title":"Endocrine"},{"key":"2634_CR14","doi-asserted-by":"crossref","unstructured":"S. De Leo, M. Di Stefano, L. Persani, L. Fugazzola, C. Colombo, Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival. Endocrine. (2020). [Online ahead of print]","DOI":"10.1007\/s12020-020-02477-0"},{"key":"2634_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009)","journal-title":"Eur. J. Cancer"},{"key":"2634_CR16","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.beem.2017.04.012","volume":"31","author":"C Resteghini","year":"2017","unstructured":"C. Resteghini, S. Cavalieri, D. Galbiati, R. Granata, S. Alfieri, C. Bergamini, P. Bossi, L. Licitra, L. Locati, Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients. Best. Pract. Res. Clin. Endocrinol. Metab. 31, 349\u2013361 (2017)","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"2634_CR17","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3389\/fendo.2018.00244","volume":"9","author":"T Porcelli","year":"2018","unstructured":"T. Porcelli, F. Sessa, A. Caputo, C. Catalini, D. Salvatore, Teriparatide replacement therapy for hypoparathyroidism during treatment with lenvatinib for advanced thyroid cancer: a case report. Front. Endocrinol. (Lausanne) 9, 244 (2018)","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"2634_CR18","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1530\/ERC-18-0049","volume":"25","author":"AG Gianoukakis","year":"2018","unstructured":"A.G. Gianoukakis, C.E. Dutcus, N. Batty, M. Guo, M. Baig, Prolonged duration of response in lenvatinib responders with thyroid cancer. Endocr. Relat. Cancer 25, 699\u2013704 (2018)","journal-title":"Endocr. Relat. Cancer"},{"key":"2634_CR19","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.1210\/jc.2015-3989","volume":"101","author":"B Robinson","year":"2016","unstructured":"B. Robinson, M. Schlumberger, L.J. Wirth, C.E. Dutcus, J. Song, M.H. Taylor, S.B. Kim, M.K. Krzyzanowska, J. Capdevila, S.I. Sherman, M. Tahara, Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer. J. Clin. Endocrinol. Metab. 101, 4103\u20134109 (2016)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2634_CR20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000502229","volume":"8","author":"L Fugazzola","year":"2019","unstructured":"L. Fugazzola, R. Elisei, D. Fuhrer, B. Jarzab, S. Leboulleux, K. Newbold, J. Smit, 2019 European Thyroid Association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer. Eur. Thyroid J. 8, 227\u2013245 (2019)","journal-title":"Eur. Thyroid J."},{"key":"2634_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ejca.2018.10.002","volume":"106","author":"M Tahara","year":"2019","unstructured":"M. Tahara, M.S. Brose, L.J. Wirth, T. Suzuki, H. Miyagishi, K. Fujino, C.E. Dutcus, A. Gianoukakis, Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer. Eur. J. Cancer 106, 61\u201368 (2019)","journal-title":"Eur. J. Cancer"},{"key":"2634_CR22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s12020-017-1233-5","volume":"56","author":"RI Haddad","year":"2017","unstructured":"R.I. Haddad, M. Schlumberger, L.J. Wirth, E.J. Sherman, M.H. Shah, B. Robinson, C.E. Dutcus, A. Teng, A.G. Gianoukakis, S.I. Sherman, Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. Endocrine 56, 121\u2013128 (2017)","journal-title":"Endocrine"},{"key":"2634_CR23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1530\/ERC-17-0016","volume":"24","author":"MS Brose","year":"2017","unstructured":"M.S. Brose, J. Smit, C.C. Lin, F. Pitoia, M. Fellous, Y. DeSanctis, M. Schlumberger, M. Tori, I. Sugitani, Timing of multikinase inhibitor initiation in differentiated thyroid cancer. Endocr. Relat. Cancer 24, 237\u2013242 (2017)","journal-title":"Endocr. Relat. Cancer"},{"key":"2634_CR24","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2014.104","volume":"11","author":"DR Camidge","year":"2014","unstructured":"D.R. Camidge, W. Pao, L.V. Sequist, Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat. Rev. Clin. Oncol. 11, 473\u2013481 (2014)","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2634_CR25","doi-asserted-by":"crossref","unstructured":"C. Giani, L. Valerio, A. Bongiovanni, C. Durante, G. Grani, T. Ibrahim, S. Mariotti, M. Massa, F. Pani, G. Pellegriti, T. Porcelli, D. Salvatore, M. Tavarelli, M. Torlontano, L. Locati, E. Molinaro, R. Elisei, Safety and quality of life data from an Italian expanded access program of lenvatinib for treatment of thyroid cancer. Thyroid. (2020). [Online ahead of print]","DOI":"10.1089\/thy.2020.0276"},{"key":"2634_CR26","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s40618-019-1001-x","volume":"42","author":"T Porcelli","year":"2019","unstructured":"T. Porcelli, F. Sessa, C. Luongo, D. Salvatore, Local ablative therapy of oligoprogressive TKI-treated thyroid cancer. J. Endocrinol. Invest. 42, 871\u2013879 (2019)","journal-title":"J. Endocrinol. Invest."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02634-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-021-02634-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02634-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T18:40:15Z","timestamp":1625683215000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-021-02634-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,3]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["2634"],"URL":"https:\/\/doi.org\/10.1007\/s12020-021-02634-z","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,3]]},"assertion":[{"value":"5 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by Institutional Review Board of the University Hospital \u201cFederico II\u201d of Naples.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent for research participation and for the publication of indirectly identifiable data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}